Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults

doi:10.1016/0264-410X(90)90049-R

Vaccine

Volume 8, Issue 3, June 1990, Pages 217-224

https://doi.org/10.1016/0264-410X(90)90049-R Get rights and content

Abstract

The effects of intranasal inoculation with live attenuated, CR influenza virus vaccines on pulmonary function in healthy and asthmatic adults were evaluated in placebo-controlled, double-blind studies. In 46 healthy adult volunteers, there were no statistically significant alterations in pulmonary function as measured by spirometry and histamine bronchoprovocation tests in the first week following monovalent CR influenza virus vaccine [type A (H3N2, H1N1) and type B]. Among healthy adults with pre-inoculation PC_20s < 10 mgml⁻¹, $812$ were infected following vaccination but no significant alterations occurred in histamine bronchoprovocation. In 11 asthmatic adults, no statistically significant alterations in pulmonary function, as measured by spirometry, were noted during the first 7 days postinoculation with bivalent CR influenza virus vaccine type A (H3N2 and H1N1). Postinoculation respiratory illnesses were more common in CR influenza virus vaccine recipients than placebo recipients, but they were mild, consisting of a febrile pharyngitis and transient rhinorrhea. Attenuated CR influenza virus vaccines do not appear to impair pulmonary function during the first week following immunization of healthy and asthmatic adults.

References (56)

D.S. Fedson
Influenza and pneumococcal immunization strategies for physicians
Chest
(1987)
J.J. Picken et al.
Prolonged effects of viral infections of the upper respiratory tract upon small airways
Am. J. Med.
(1972)
W.W. Storms et al.
Intranasal immunization with attenuated live influenza vaccine in asthma
J. Allergy Clin. Immunol.
(1976)
B.E. Pennock et al.
Changes in measured spirometric indices: what is significant?
Chest
(1981)
H. Chai et al.
Standardization of bronchial inhalation challenge procedures
J. Allergy Clin. Immunol.
(1975)
F.E. Hargreave et al.
Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance
J. Allergy Clin. Immunol.
(1981)
J.N. Greene
Subacute thyroiditis
Am. J. Med.
(1971)
J.J. Ouellette et al.
Increased response of asthmatic subjects to methacholine after influenza vaccine
J. Allergy
(1965)
S.C. Anand et al.
Effect of influenza vaccine on methacholine (Mecholyl) sensitivity in patients with asthma of known and unknown origin
J. Allergy
(1968)
T.D. Bell et al.
Immunization with killed influenza virus in children with chronic asthma
Chest
(1978)

B. Stenius-Aarniala et al.

Lack of clinical exacerbations in adults with chronic asthma after immunization with killed influenza virus

Chest

(1986)

S.D. Collins et al.

Trends and epidemics of influenza and pneumonia, 1918–1951

Public Health Rep.

(1951)

J. Housworth et al.

Excess mortality from epidemic influenza, 1957–1966

Am. J. Epidemiol.

(1974)

D.W. Alling et al.

A study of excess mortality during influenza epidemics in the United States, 1968–1976

Am. J. Epidemiol.

(1981)

E.D. Kilbourne et al.

Influenza vaccines—Summary of Influenza Workshop

H.T. Blair et al.

Effects of rhinovirus infection on pulmonary function of healthy human volunteers

Am. Rev. Respir. Dis.

(1976)

A.T. Aquilina et al.

Airway reactivity in subjects with viral upper respiratory tract infections: The effects of exercise and cold air

Am. Rev. Respir. Dis.

(1980)

W.J. Hall et al.

Respiratory syncytial virus infection in adults

Ann. Intern. Med.

(1978)

D.W. Empey et al.

Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection

Am. Rev. Respir. Dis.

(1976)

T.R. Cate et al.

Effects of common colds on pulmonary function

Am. Rev. Respir. Dis.

(1973)

W.W. Fridy et al.

Airways function during mild viral respiratory illnesses

Ann. Intern. Med.

(1974)

W.G. Johanson et al.

Pulmonary function in uncomplicated influenza

Am. Rev. Respir. Dis.

(1969)

S.R. Leeder et al.

Short and long term effects of influenza A on lung function

Med. J. Austral.

(1974)

G.J. Horner et al.

Effect of uncomplicated, presumptive influenza on the diffusing capacity of the lung

Am. Rev. Respir. Dis.

(1973)

J.W. Little et al.

Airway hyperreactivity and peripheral airway dysfunction in influenza A infection

Am. Rev. Respir. Dis.

(1978)

W.J. Utell et al.

Development of airway reactivity to nitrates in subjects with influenza

Am. Rev. Respir. Dis.

(1980)

J.W. Little et al.

Amantadine effect on peripheral airways abnormalities in influenza

W.J. Hall et al.

Pulmonary mechanics after uncomplicated influenza A infection

Am. Rev. Respir. Dis.

(1976)

Cited by (28)

Vaccinating High-Risk Children with the Intranasal Live-Attenuated Influenza Vaccine: The Quebec Experience
2014, Paediatric Respiratory Reviews
Citation Excerpt :
Redding et al [27] enrolled 48 children with asthma and demonstrated no significant difference between the group receiving LAIV and placebo with respect to change in forced expiratory volume (FEV1), the number of asthma exacerbations, the number of participants with a reduction in peak expiratory flow rate of 15% or 30%, or the number of participants who used β-agonists as a rescue measure. Combining these results with those of Atmar et al (n = 17 children with asthma) [28], the authors of the Cochrane review reported no difference in risk of decreased FEV1 2-4 days post vaccination (risk difference: 0.01, 95% CI: -0.12, 0.15). Fleming et al. randomized over 2000 asthmatic participants aged 6 to 17 years to receive LAIV or IIV.
Given the burden of illness associated with influenza, vaccination is recommended for individuals at high risk of complications. The live-attenuated influenza vaccine (LAIV) is administered by intranasal spray, thus directly stimulating mucosal immunity. In this review, we aimed to provide evidence for its efficacy and safety in different paediatric populations. We also share the Quebec experience of LAIV use through a publicly funded vaccination program for children with chronic, high-risk conditions.
from randomized controlled trials in healthy children and in asthmatics have demonstrated superior efficacy of LAIV over the injectable vaccine (IIV). LAIV is well tolerated: its administration is associated with runny nose and nasal congestion, but not with asthma exacerbations and is well tolerated in children with cystic fibrosis, when compared to IIV. The vaccine is well accepted by children and parents and can easily be part of vaccination clinics in paediatric tertiary care centres targeting children with chronic, high-risk conditions, not leading to immunosuppression.
Influenza (Including Avian Influenza and Swine Influenza)
2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
Current issues with influenza vaccination in egg allergy
2002, Journal of Allergy and Clinical Immunology
Influenza infection, with its accompanying morbidity and mortality, represents a major public health concern yearly to the elderly and high-risk groups, including asthmatic patients. Active prevention with vaccination consistently falls short of reaching optimal immunization rates in all risk groups. Asthmatic patients and others with concomitant egg allergy might be denied active immunization because of the risk of inducing adverse reactions with a vaccine derived from egg embryo tissue. Evidence supports the relatively safe administration of influenza vaccine to individuals with egg allergy in whom vaccination is indicated when specific protocols are followed under the supervision of experienced physicians. A practical protocol that includes incremental dosing of influenza vaccine is presented to guide clinicians in influenza vaccination in this high-risk group. (J Allergy Clin Immunol 2002;110:834-40.)
Rationale and approach to target children with asthma for annual influenza immunization
2002, Seminars in Pediatric Infectious Diseases
Citation Excerpt :
Data on safety and effectiveness of live-attenuated, cold-recombinant (CR) influenza vaccines in persons with asthma are limited. A study of 11 asthmatic adults demonstrated no significant alteration in pulmonary function in the week after receiving vaccination with a bivalent CR vaccine.59 A study of institutionalized children in Japan who received the trivalent CR vaccine noted no serious adverse events in 19 asthmatic children, and none of the vaccinees and 25 percent of the nonvaccinees subsequently were infected with influenza A (H1N1).60
Influenza virus infection can cause an acute exacerbation of asthma that may result in hospitalization. Annual influenza vaccination is recommended for children with asthma, but fewer than 10 percent receive it. This review summarizes the influenza-associated morbidity in children with asthma. The risk-versus-benefit of influenza vaccination in children with asthma is evaluated. Strategies to improve influenza vaccine uptake in children with asthma are investigated. Influenza virus infection causes substantial morbidity in children with asthma. Data on safety and effectiveness of the trivalent influenza vaccine in these children are limited. However, it is generally safe and effective in preventing influenza infection. The investigational live-attenuated, cold-adapted, trivalent nasal spray influenza vaccine needs evaluation for safety and efficacy in children with asthma. An annual, well-organized, computerized multicomponent strategy should be implemented for optimizing influenza immunization in the high-risk population. Children with asthma should be targeted for annual influenza immunization. Copyright 2002, Elsevier Science (USA). All rights reserved.
Promises and challenges of live-attenuated intranasal influenza vaccines across the age spectrum: A review
2000, Biomedicine and Pharmacotherapy
Despite the availability of inactivated influenza vaccines, influenza continues to cause considerable mortality in the elderly, and morbidity in all age groups. Cold-adapted, live-attenuated, intranasally administered influenza vaccines, first developed in the 1960s, have been tested in more than 10,000 volunteers and have been shown to be safe, well-tolerated, and immunogenic. Recent trials suggest that efficacy in children may be superior to that of inactivated vaccines, and efficacy in healthy adults may be similar to that of inactivated vaccines, although there are limited data comparing the two vaccines directly. Advantages of the live-attenuated vaccines include acceptability, ease of administration, and the potential for mass immunization. The possibility of substantially higher vaccination rates across all age groups brings promise for the development of herd immunity and greatly improved control of influenza in the future.
Respiratory viral infections in the elderly
1999, Antiviral Research

View all citing articles on Scopus

View full text

PaperEffect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults

Abstract

Chest

Am. J. Med.

J. Allergy Clin. Immunol.

Chest

J. Allergy Clin. Immunol.

J. Allergy Clin. Immunol.

Am. J. Med.

J. Allergy

J. Allergy

Chest

Chest

Trends and epidemics of influenza and pneumonia, 1918–1951

Public Health Rep.

Excess mortality from epidemic influenza, 1957–1966

Am. J. Epidemiol.

A study of excess mortality during influenza epidemics in the United States, 1968–1976

Am. J. Epidemiol.

Influenza vaccines—Summary of Influenza Workshop

Effects of rhinovirus infection on pulmonary function of healthy human volunteers

Am. Rev. Respir. Dis.

Airway reactivity in subjects with viral upper respiratory tract infections: The effects of exercise and cold air

Am. Rev. Respir. Dis.

Respiratory syncytial virus infection in adults

Ann. Intern. Med.

Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection

Am. Rev. Respir. Dis.

Effects of common colds on pulmonary function

Am. Rev. Respir. Dis.

Airways function during mild viral respiratory illnesses

Ann. Intern. Med.

Pulmonary function in uncomplicated influenza

Am. Rev. Respir. Dis.

Short and long term effects of influenza A on lung function

Med. J. Austral.

Effect of uncomplicated, presumptive influenza on the diffusing capacity of the lung

Am. Rev. Respir. Dis.

Airway hyperreactivity and peripheral airway dysfunction in influenza A infection

Am. Rev. Respir. Dis.

Development of airway reactivity to nitrates in subjects with influenza

Am. Rev. Respir. Dis.

Amantadine effect on peripheral airways abnormalities in influenza

Pulmonary mechanics after uncomplicated influenza A infection

Am. Rev. Respir. Dis.

Paper
Effect of live attenuated, cold recombinant (CR) influenza virus vaccines on pulmonary function in healthy and asthmatic adults